Glass Lewis Backs PVG's Proxy Fight, Recommends Against Anavex Chair and One Other Incumbent
AVXL is trading near its 52-week low of $2.255 (7.1% above the low) on light trading volume (0.1× avg).
Summary
Glass Lewis recommended Anavex stockholders vote the GOLD Universal Proxy Card, supporting two PVG nominees and opposing incumbent chair Jiong Ma and director Claus van der Velden, citing 'functionally inert stewardship.'
Key Events · Corporate Governance and Compliance · AVXL
-
Glass Lewis Backs PVG Slate
Glass Lewis recommended stockholders vote the GOLD Universal Proxy Card, supporting PVG nominees Curtis Hogue and Jason Kolbert and opposing incumbent chair Jiong Ma and director Claus van der Velden.
-
Advisor Cites Ineffective Oversight
Glass Lewis stated the incumbent board's oversight has been 'measurably ineffective' and that 'functionally inert stewardship' contributed to strategic turbulence, executive tumult, regulatory lapses, and persistent downside performance.
-
Director Economic Exposure Questioned
Glass Lewis noted one current director owns just 5,000 shares, the rest of the board's beneficial ownership is in underwater options, and three of the company's director nominees have no economic exposure to Anavex.
-
September 24 Vote Looms
The recommendation lands one week before the September 24, 2026 annual meeting, where PVG seeks to replace the entire six-member board.
Analysis · AVXL · Life Sciences
Glass Lewis, one of the two dominant proxy advisory firms, has formally sided with activist PVG Asset Management in the September 24 board contest. The recommendation to vote against incumbent chair Jiong Ma and director Claus van der Velden — while supporting two PVG nominees — materially shifts the odds in a fight where PVG holds only 337,663 shares. Proxy advisor endorsements routinely swing institutional votes, and Glass Lewis's unusually blunt language ('measurably ineffective,' 'functionally inert stewardship') gives PVG's campaign a credibility boost it lacked when it was a lone activist voice.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVXL was trading at $2.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $223.9M. The 52-week trading range was $2.26 to $10.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.